The largest pharmaceutical company in Asia

News

  • News
  • 16 Jan 2020
    • Share

Japanese Giant Takeda Announces 2040 Carbon Neutrality Goal

The largest pharmaceutical company in Asia, Takeda, has announced its commitment to fighting climate change with new pledges for 2020. The company has set an objective of achieving carbon neutrality across its entire value chain by 2040, with a goal of reducing carbon emissions by 40 percent by 2025. The new targets follow Takeda meeting its previous target of reducing CO2 emissions by 33.7 percent by 2020. Takeda is also aiming to improve the environmental performance of its suppliers and partner companies too through its sustainability strategy. President and CEO, Christophe Weber said in a statement “we also recognise that supporting our patients means we must commit to work on behalf of the broader global community – and one way to do this is by accelerating our environmental efforts.” The Japanese giant employs almost 50,000 people worldwide and achieved revenues of US$19.3 billion in 2018, meaning any lead it takes on eco-streamlining operations has the potential of impacting and influencing the rest of the industry.

Posted by

CSO